Cardiac hypertrophy is an independent risk factor for sudden cardiac death in clinical settings and the incidence of sudden cardiac death and ventricular arrhythmias are closely related. The aim of this study was to determine the effects of the calmodulin-dependent protein kinase (CaMK) II inhibitor, KN-93, on L-type calcium current (I-Ca,I- L) and early after-depolarizations (EADs) in hypertrophic cardiomyocytes. A rabbit model of myocardial hypertrophy was constructed through abdominal aortic coarctation (LVH group). The control group (sham group) received a sham operation, in which the abdominal aortic was dissected but not coarcted. Eight weeks later, the degree of left ventricular hypertrophy (LVH) was evaluated using echocardiography. Individual cardiomyocyte was isolated through collagenase digestion. Action potentials (APs) and I-Ca,I- L were recorded using the perforated patch clamp technique. APs were recorded under current clamp conditions and I-Ca,I- L was recorded under voltage clamp conditions. The incidence of EADs and I-ca,I- L in the hypertrophic cardiomyocytes were observed under the conditions of low potassium (2 mmol/L), low magnesium (0.25 mmol/L) Tyrode's solution perfusion, and slow frequency (0.25-0.5 Hz) electrical stimulation. The incidence of EADs and I-ca,I- L in the hypertrophic cardiomyocytes were also evaluated after treatment with different concentrations of KN-92 (KN-92 group) and KN-93 (KN-93 group). Eight weeks later, the model was successfully established. Under the conditions of low potassium, low magnesium Tyrode's solution perfusion, and slow frequency electrical stimulation, the incidence of EADs was 0/12, 11/12, 10/12, and 5/12 in sham group, LVH group, KN-92 group (0.5 mu mol/L), and KN-93 group (0.5 mu mol/L), respectively. When the drug concentration was increased to 1 mu mol/L in KN-92 group and KN-93 group, the incidence of EADs was 10/12 and 2/12, respectively. At 0 mV, the current density was 6.7 +/- 1.0 and 6.3 +/- 0.7 PA center dot PF-1 in LVH group and sham group, respectively (P > 0.05, n=12). When the drug concentration was 0.5 mu mol/L in KN-92 and KN-93 groups, the peak I-Ca,I- L at 0 mV was decreased by (9.4 +/- 2.8)% and (10.5 +/- 3.0)% in the hypertrophic cardiomyocytes of the two groups, respectively (P > 0.05, n=12). When the drug concentration was increased to 1 mu mol/L, the peak I-Ca,I- L values were lowered by (13.4 +/- 3.7)% and (40 +/- 4.9)%, respectively (P < 0.01, n=12). KN-93, a specific inhibitor of CaMKII, can effectively inhibit the occurrence of EADs in hypertrophic cardiomyocytes partially by suppressing I-Ca,I- L, which may be the main action mechanism of KN-93 antagonizing the occurrence of ventricular arrhythmias in hypertrophic myocardium.